Interferon-α as maintenance therapy in patients with multiple myeloma

Annals of Oncology

Volumn 16, Issue 4, 2005, Pages 634-639

  Schaar, C G ^a   Kluin Nelemans, H C ^b   te Marvelde, C ^c   le Cessie, S ^d   Breed, W P ^e   Fibbe, W E ^d   van Deijk, W A ^f   Fickers, M M ^g   Roozendaal, K J ^h   Wijermans, P W ⁱ  

^a GELRE HOSPITALS   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Integraal Kankercentrum West   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

^f Red Cross Hospital Den Haag   (Netherlands)

^g Sittard Geleen Heerlen   (Netherlands)

^h Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

ⁱ LEYENBURG HOSPITAL   (Netherlands)

Author keywords

Interferon ; Maintenance therapy; Multiple myeloma

Indexed keywords

ALPHA2B INTERFERON; M PROTEIN; MELPHALAN; PREDNISONE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TOXICITY; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LABORATORY DIAGNOSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MULTIPLE MYELOMA; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 20944446210     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi125     Document Type: Article

References (10)

1. Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
2. The Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020-1034.
3. Fritz E, Ludwig H. Interferon-α treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000; 11: 1427-1436.
4. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
5. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034-1038.
6. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
7. The Nordic Myeloma Study Group. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. Ann Intern Med 1996; 124: 212-222.
8. Ludwig H, Cohen AM, Polliack A et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995; 6: 467-476.
9. Zee B, Cole B, Li T et al. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol 1998; 16: 2834-2839.
10. Wisloff F, Eika S, Hippe E et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1996; 92: 604-613.